Heartbeam (BEAT) Investor presentation summary

Market opportunity and unmet need

• Over 50 million patients in the U.S. could benefit from advanced cardiac monitoring, representing a $40B market opportunity across multiple segments including concierge, preventive cardiology, and high-risk populations.

• Current consumer ECG devices lack the spatial orientation and diagnostic capability for ischemia detection, while traditional 12-lead ECGs are limited to clinical settings.

• Patient delays in seeking care for cardiac events significantly increase risk and cost, with no dependable at-home solution currently available.

Technology and product platform

• Platform features a patented, cable-free, synthesized 12-lead ECG for at-home arrhythmia assessment, FDA-cleared for this indication.

• Proprietary 3D signal collection and personalized algorithms enable real-time, physician-ready ECG readouts in a compact, credit card-sized device.

• Two main form factors: a handheld system for episodic monitoring and an on-demand 12-lead patch for continuous monitoring.

Commercialization and go-to-market strategy

• Initial focus on concierge and preventive cardiology practices, targeting 1.5M patients with rapid adoption and efficient sales processes.

• Expansion planned into national chains and broader patient pay markets, leveraging proof points from initial launches.

• High-margin, subscription-based business model with a short payback period and scalable implementation.